atezolizumab + nab-paclitaxel + gemcitabine

Atezolizumab + nab-paclitaxel + gemcitabine is a three-drug combination used in oncology research, most notably for advanced pancreatic cancer. **Atezolizumab** is a humanized monoclonal antibody immunotherapy that acts as a checkpoint inhibitor by selectively binding to PD-L1 (Programmed death-ligand 1), thereby activating anti-tumor immunity. **Nab-paclitaxel** is paclitaxel bound to albumin nanoparticles, enhancing tumor delivery, and acts as a cytotoxic agent by stabilizing microtubules. **Gemcitabine** is a nucleoside analog that inhibits DNA synthesis. This combination is under investigation as a first-line or subsequent-line treatment for metastatic or locally advanced pancreatic cancer and other tumors, but is not a globally approved regimen at this time.

Other names

atezolizumab plus nab-paclitaxel plus gemcitabine